Kwality Pharmaceuticals (539997) Q1 25/26 earnings summary

Executive summary

• Consolidated revenue grew 39.8% year-over-year to ₹111.8 crore in Q1 FY26, driven by international sales of registered products.

• Net profit increased 43% year-over-year to ₹11.9 crore, reflecting improved scale and operational efficiency.

• Regulatory milestones included a successful Zimbabwe audit and upcoming EU-GMP and WHO-GMP inspections, supporting global expansion.

• Multiple new product registrations and international marketing initiatives are expected to support the FY26 revenue target of ₹500 crore.

Financial highlights

• Consolidated revenue for Q1 FY26: ₹11147.90 lakh, up from ₹8007.89 lakh in Q1 FY25.

• EBITDA rose 39% year-over-year to ₹24.6 crore; EBITDA margin stable at ~22%.

• Net profit after tax for Q1 FY26: ₹1191.97 lakh, up from ₹834.64 lakh in Q1 FY25.

• Basic and diluted EPS for Q1 FY26: ₹11.49, compared to ₹8.04 in Q1 FY25.

• Total comprehensive income for Q1 FY26: ₹1207.08 lakh, up from ₹844.00 lakh in Q1 FY25.

Outlook and guidance

• Targeting ₹500 crore in revenue for FY26, supported by new product registrations and international expansion.

• EU-GMP audit scheduled for October and WHO-GMP inspection for biologics facility planned later in the year.

• Ongoing investments in production capacity and clinical trials for biologics, including Erythropoietin (EPO).